Department of Dermatology, University Hospital Ramón y Cajal, Madrid, Spain; Dermatology Group Pedro Jaén, Madrid, Spain.
Department of Dermatology, University Hospital Ramón y Cajal, Madrid, Spain; Dermatology Group Pedro Jaén, Madrid, Spain.
J Am Acad Dermatol. 2021 May;84(5):1285-1294. doi: 10.1016/j.jaad.2020.09.093. Epub 2020 Oct 7.
Dutasteride has been proposed as an effective therapy for frontal fibrosing alopecia (FFA).
We sought to describe the therapeutic response to dutasteride and the most effective dosage in FFA compared with other therapeutic options or no treatment.
This was a retrospective observational study including patients with FFA with a minimum follow-up of 12 months. Therapeutic response was evaluated according to the stabilization of the hairline recession.
A total of 224 patients (222 females) with a median follow-up of 24 months (range 12-108 months) were included. The stabilization rate for the frontal, right, and left temporal regions after 12 months was 62%, 64%, and 62% in the dutasteride group (n = 148), 60%, 35%, and 35% with other systemic therapies (n = 20), and 30%, 41%, and 38% without systemic treatment (n = 56; P = .000, .006, and .006, respectively). Stabilization showed a statistically significant association with an increasing dose of dutasteride (88%, 91%, and 84% with a weekly treatment of 5 or 7 doses of 0.5 mg [n = 32], P < .005). Dutasteride was well tolerated in all patients.
Limitations included the observational and retrospective design.
Oral dutasteride was the most effective therapy with a dose-dependent response for FFA in real clinical practice compared with other systemic therapies or no systemic treatment.
非那雄胺已被提议作为治疗额部纤维性脱发(FFA)的有效疗法。
我们旨在描述非那雄胺治疗 FFA 的疗效,以及与其他治疗选择或不治疗相比,最有效的剂量。
这是一项回顾性观察性研究,纳入了至少随访 12 个月的 FFA 患者。根据发际线后退的稳定情况评估治疗反应。
共纳入 224 例(222 例女性)患者,中位随访时间为 24 个月(范围 12-108 个月)。在非那雄胺组(n=148),治疗 12 个月后,额部、右侧和左侧颞部的稳定率分别为 62%、64%和 62%;其他全身治疗组(n=20)分别为 60%、35%和 35%;未全身治疗组(n=56)分别为 30%、41%和 38%(P 值分别为.000、.006 和.006)。稳定与非那雄胺剂量的增加呈统计学显著相关(每周治疗 5 或 7 次 0.5mg 剂量的患者分别为 88%、91%和 84%[n=32],P<.005)。所有患者均耐受良好。
包括观察性和回顾性设计的局限性。
与其他全身治疗或不进行全身治疗相比,在真实临床实践中,口服非那雄胺是治疗 FFA 最有效的药物,且具有剂量依赖性反应。